Protein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade. Protein C is a zymogen, or enzyme precursor, of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). Once in its activated form, APC functions as a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S. APC exerts its effect by inactivating essential components of the coagulation cascade (specifically factors V and VIII), which leads to a decrease in thrombin formation, and therefore a reduction in clot formation.
The Protein C pathway provides a natural mechanism for control of the coagulation system and prevention of excessive procoagulant responses to activating stimuli. A lack of protein C in the body would lead to unchecked coagulation activation, resulting in thrombin generation and intravascular clot formation.
Protein C is available in concentrated form as the product Ceprotin, which is indicated for use in pediatric and adult patients with severe congenital protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | Apixaban may increase the anticoagulant activities of Protein C. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of Protein C. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Protein C. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when Protein C is combined with Deferasirox. |
| Ursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Protein C is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Protein C is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of bleeding and bruising can be increased when Protein C is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of bleeding and bruising can be increased when Protein C is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of bleeding and bruising can be increased when Protein C is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of bleeding and bruising can be increased when Protein C is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of bleeding and bruising can be increased when Protein C is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Protein C is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Protein C is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Protein C is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of bleeding and bruising can be increased when Protein C is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of bleeding and bruising can be increased when Protein C is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Protein C is combined with Hyodeoxycholic Acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Protein C. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Protein C. |
| Obinutuzumab | The risk or severity of bleeding and hemorrhage can be increased when Protein C is combined with Obinutuzumab. |
| Rivaroxaban | Protein C may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when Protein C is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of Protein C. |
| Tipranavir | The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Protein C. |
| Urokinase | Urokinase may increase the anticoagulant activities of Protein C. |
| Vitamin E | Vitamin E may increase the anticoagulant activities of Protein C. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Protein C. |
| Aprotinin | The therapeutic efficacy of Protein C can be decreased when used in combination with Aprotinin. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of Protein C. |
| Ifosfamide | The risk or severity of bleeding can be increased when Ifosfamide is combined with Protein C. |
| Quinine | The therapeutic efficacy of Protein C can be increased when used in combination with Quinine. |
| Quinidine | The therapeutic efficacy of Protein C can be increased when used in combination with Quinidine. |
| Tamoxifen | The risk or severity of bleeding can be increased when Tamoxifen is combined with Protein C. |
| Toremifene | The risk or severity of bleeding can be increased when Toremifene is combined with Protein C. |
| Pentoxifylline | The therapeutic efficacy of Protein C can be increased when used in combination with Pentoxifylline. |
| Pentosan polysulfate | Pentosan polysulfate may increase the anticoagulant activities of Protein C. |
| Levocarnitine | The therapeutic efficacy of Protein C can be increased when used in combination with Levocarnitine. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the anticoagulant activities of Protein C. |
| Chlorotrianisene | Chlorotrianisene may decrease the anticoagulant activities of Protein C. |
| Conjugated estrogens | Conjugated estrogens may decrease the anticoagulant activities of Protein C. |
| Mestranol | The risk or severity of adverse effects can be increased when Mestranol is combined with Protein C. |
| Estrone sulfate | Estrone sulfate may decrease the anticoagulant activities of Protein C. |
| Quinestrol | Quinestrol may decrease the anticoagulant activities of Protein C. |
| Hexestrol | Hexestrol may decrease the anticoagulant activities of Protein C. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Protein C. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Protein C. |
| Polyestradiol phosphate | Polyestradiol phosphate may decrease the anticoagulant activities of Protein C. |
| Esterified estrogens | Esterified estrogens may decrease the anticoagulant activities of Protein C. |
| Zeranol | Zeranol may decrease the anticoagulant activities of Protein C. |
| Equol | Equol may decrease the anticoagulant activities of Protein C. |
| Methallenestril | Methallenestril may decrease the anticoagulant activities of Protein C. |
| Epimestrol | Epimestrol may decrease the anticoagulant activities of Protein C. |
| Moxestrol | Moxestrol may decrease the anticoagulant activities of Protein C. |
| Estradiol acetate | Estradiol acetate may decrease the anticoagulant activities of Protein C. |
| Estradiol benzoate | Estradiol benzoate may decrease the anticoagulant activities of Protein C. |
| Estradiol cypionate | Estradiol cypionate may decrease the anticoagulant activities of Protein C. |
| Estradiol valerate | Estradiol valerate may decrease the anticoagulant activities of Protein C. |
| Biochanin A | Biochanin A may decrease the anticoagulant activities of Protein C. |
| Formononetin | Formononetin may decrease the anticoagulant activities of Protein C. |
| Estriol | Estriol may decrease the anticoagulant activities of Protein C. |
| Icosapent | The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Protein C. |
| Mesalazine | The risk or severity of bleeding can be increased when Mesalazine is combined with Protein C. |
| Indomethacin | The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Protein C. |
| Nabumetone | The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Protein C. |
| Ketorolac | The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Protein C. |
| Tenoxicam | The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Protein C. |
| Celecoxib | The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Protein C. |
| Tolmetin | The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Protein C. |
| Rofecoxib | The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Protein C. |
| Piroxicam | The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Protein C. |
| Fenoprofen | The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Protein C. |
| Valdecoxib | The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Protein C. |
| Diclofenac | The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Protein C. |
| Sulindac | The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Protein C. |
| Flurbiprofen | The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Protein C. |
| Etodolac | The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Protein C. |
| Mefenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Protein C. |
| Naproxen | The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Protein C. |
| Sulfasalazine | The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Protein C. |
| Phenylbutazone | The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Protein C. |
| Meloxicam | The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Protein C. |
| Carprofen | The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Protein C. |
| Diflunisal | The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Protein C. |
| Salicylic acid | The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Protein C. |
| Meclofenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Protein C. |
| Oxaprozin | The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Protein C. |
| Ketoprofen | The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Protein C. |
| Balsalazide | The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Protein C. |
| Olsalazine | The risk or severity of bleeding can be increased when Olsalazine is combined with Protein C. |
| Lumiracoxib | The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Protein C. |
| Magnesium salicylate | The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Protein C. |
| Salsalate | The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Protein C. |
| Choline magnesium trisalicylate | The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Protein C. |
| Antrafenine | The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Protein C. |
| Aminophenazone | The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Protein C. |
| Antipyrine | The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Protein C. |
| Tiaprofenic acid | The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Protein C. |
| Etoricoxib | The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Protein C. |
| Taxifolin | The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Protein C. |
| Oxyphenbutazone | The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Protein C. |